These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 31564852

  • 1. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 3. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 4. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 6. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.
    BMC Pulm Med; 2021 Jul 31; 21(1):253. PubMed ID: 34332555
    [Abstract] [Full Text] [Related]

  • 7. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 31; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

  • 8. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 31; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
    Moretz C, Cole AL, Mu G, Wu B, Guisinger A, Liu Y, Hahn B, Baylis L.
    Int J Chron Obstruct Pulmon Dis; 2020 Jul 31; 15():2207-2215. PubMed ID: 32982213
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 31; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J, Zhong N, Newlands A, Church A, Goh AH.
    Int J Chron Obstruct Pulmon Dis; 2015 Jul 31; 10():1753-67. PubMed ID: 26366068
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF, Beeh KM, Schultze M, Kossack N, Richter LM, Claussen J, Compton C, Noorduyn SG, Ismaila AS, Requena G.
    Int J Chron Obstruct Pulmon Dis; 2024 Jul 31; 19():1835-1848. PubMed ID: 39140078
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2024 Jul 31; 19():945-956. PubMed ID: 38646606
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 15. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 20; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 16. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul 20; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 17. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 20; 11():1413-24. PubMed ID: 27445468
    [Abstract] [Full Text] [Related]

  • 18. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 20; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 19. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J.
    J Manag Care Spec Pharm; 2020 Oct 20; 26(10):1363-1374. PubMed ID: 32678719
    [Abstract] [Full Text] [Related]

  • 20. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 20; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.